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Our vision at the National Cancer Institute (NCI) is
to stimulate and support scientiﬁc discovery and its ap-
plication to achieve a future when all cancers are uncom-
mon and easily treated. Cancer researchers have made sig-
niﬁcant progress but extensive work remains. In 2003, in
USAalone,1.3millionpeoplewerediagnosedwithcancer
andover500000deathsoccurredbecauseofcancer.Tech-
nology continues to help us make major strides in under-
standingthemolecularbasisofcancer,andwillbeamajor
force in developing new diagnostics and interventions.
A critical technology in the ﬁght against cancer is in
vivo imaging. Detection through imaging of the molecu-
lar changes associated with a tumor cell will improve our
abilitytodetectandstagetumors,selectappropriatetreat-
ments, monitor the eﬀectiveness of treatment, and deter-
mine prognosis.
The role of imaging in cancer research is changing.
Historically the focus was on anatomic imaging, with an
emphasis on developing clearer and more detailed pic-
t u r e so fo r g a n sa n dt i s s u e s .N o wt h ef o c u si so nf u n c -
tional imaging, emphasizing the physiological, cellular, or
molecular processes in living tissues, as they take place.
(As Richard Klausner noted when he was the NCI Direc-
tor, imaging used to be “location, location, location,” in
the future it will be “information, information, informa-
tion.”)
The NCI has developed programs to move imaging
into roles such as determining the pathogenesis of risk,
identifying preclinical disease, enabling drug discovery,
and facilitating tumor-selective image-guided interven-
tions (http://cip.cancer.gov). Clinically, imaging will have
a greater role in noninvasive diagnosis, identifying disease
subsets in patients, assessing therapeutic response, disease
progression, and monitoring of treatment.
We created the NCI Imaging Program in 1996, and
its resources and initiatives extend internationally. The
spectrum of research ranges from cellular to small ani-
mal to individuals to populations. Integrating scientiﬁc
disciplines such as radiology, bioengineering, biology,
chemistry,andphysicsintoateamapproachwasessential.
For example, the In Vivo Cellular and Molecular Imag-
ing Centers bring together a variety of investigators to de-
velop molecular (functional) imaging methods and tech-
niques for animals and humans. The Small Animal Imag-
ing Resource Programs make these techniques available
to researchers who need to use these imaging tools in
theirlaboratoryexperimentsonlivinganimals.Theuseof
molecular imaging techniques in small animals allows re-
searcherstomakeserialmeasurementsinthesameanimal
over days, weeks, or months. The recently formed Net-
workforTranslationalResearchinOpticalImagingbrings
together groups of investigators who are developing di-
verse optical imaging methods. Optical methods hold the
promise of providing molecular information with devices
that are relatively inexpensive, and that do not use ioniz-
ing radiation.
NCIalsohasprogramstohelpindividualinvestigators
develop novel imaging agents or new technologies. The
Development of Clinical Imaging Drugs and Enhancers
Programprovidesacademicorindustryresearcherswitha
meanstoacquirethepreclinicaldataneededtoobtainreg-
ulatory approval to test new imaging agents in humans.
For imaging device development, investigators can apply
for grants from the Exploratory/Developmental Grants
for Diagnostic Cancer Imaging initiative, or the Phased
Innovation Award (R21/R33) Program.
When new methods, devices, or imaging agents are
ready for multicenter clinical trials, investigators can sub-
mit a protocol proposal to the NCI-sponsored American
College of Radiology Imaging Network (ACRIN). For ex-
ample, ACRIN is carrying out two large screening trials,
one in women at risk for breast cancer, and the other in
collaboration with the NCI Division of Cancer Preven-
tion in individuals at risk for lung cancer. Both trials have
completedtheir50000-personaccrual.Thescreeningtrial
for lung cancer, the largest cancer killer, will determine if
lung cancer screening using two diﬀerent imaging modal-
ities, spiral CT or CXR, reduces lung-cancer-speciﬁc4 E. G. Feigal and D. C. Sullivan 2004:1 (2004)
mortality. The screening trial for breast cancer will de-
termine the screening eﬃcacy of conventional screen-ﬁlm
versus digital mammography. Novel aspects in the de-
sign of the mammography trial included the willingness
of four competing device manufacturers (GE, LoRad, Fis-
cher, and Fuji) to pool the data on this technology, and
the collaborative interactions of the ACRIN investigators
with Food and Drug Administration (FDA) and Center
for Medicare and Medicaid Services (CMS) staﬀ.W e l l -
annotated image archive databases will be available from
both of these trials. Tissue and ﬂuid specimens banked
for biomarker research will also be available fromthe lung
screening trial.
In addition to ACRIN, NCI has a program called the
Early Clinical Trials of Imaging Agents to provide funds
and infrastructureforphase 1 and phase 2 clinical trials of
new imaging agents. NCI also supports several coopera-
tive groups fortherapeuticclinicaltrials,andthesegroups
provide a resource to perform correlative imaging studies,
forexample totest theability ofimaging methods to mea-
sure tumor response to therapy.
We also recognized the need to integrate the various
aspects of the environment in which technology devel-
opers had to work to bring promising products to test-
ing and eventually to the market place to achieve an im-
pact on the public health. The NCI works with scientists,
clinicians, technology developers from academia and in-
dustry, and other federal government agencies critical to
this eﬀort, such as the three centers—Devices, Drugs, and
Biologics—of the FDA and the CMS.
We created the National Forum on Biomedical Imag-
ing in Oncology to facilitate partnerships with the imag-
ing industry and government agencies to address new
biomedical opportunities and challenges in oncology and
to focus on the regulatory, coverage, and reimbursement
issues for more developed and established technologies.
From 200 to 250 technology developers from academia
and industry, scientists, clinicians, and staﬀ from NCI,
FDA, and CMS have met in an open forum since 1999,
with the most recent meetings on January 29–30th, 2004
in Bethesda, Maryland, USA.
A new multiagency group from the NCI, FDA, and
CMS—called the Interagency Council on Biomedical
Imaging in Oncology—was created in 2000 to serve as
a conﬁdential sounding board for technology developers
from academia or industry, attempting to take emerging
medical imaging technologies to market. These conﬁden-
tial meetings are held three times per year, and provide
multiagency advice on scientiﬁc, clinical, regulatory, and
reimbursement issues. Requestors have come from large
or small companies and academia, with projects in var-
ious stages of development. The scope is broad and in-
cludes molecular probes, contrast agents, and imaging
andopticaltechnologydevices.Feedbacksuggeststhedis-
cussions have been instrumental in helping developers
make informed decisions. The venue has also focused in-
teragency discussion and heightened awareness of intera-
g e n c yp e r s p e c t i v e sa sw e l la ss t i m u l a t e dd i s c u s s i o no fn e w
and novel issues such as those associated with the devel-
opment of artiﬁcial intelligence algorithms. The next due
date for requests is June 8th, 2004 for the July 20th meet-
ing.
NCI also provides researchers in the imaging commu-
nitywithavarietyofresources.TheMouseModelsofHu-
man Cancers Consortium (http://emice.nci.nih.gov)p r o -
vides investigators with genetically engineered mice. A
database of all imaging agents, an image archive of spi-
ral CT lung scans from screened patients (Lung Image
Database Consortium), and image archives of small an-
imal imaging experiments are all under construction and
will be publicly available soon.
Noninvasiveorminimallyinvasiveimagingasameans
to obtain molecular information from and direct therapy
in living animals and patients is in the midst of an excit-
ing revolution. The entire spectrum of the clinical cancer
problem,fromriskassessmentthroughdetection,diagno-
sis, delivery and monitoring of therapy, and surveillance
for recurrence, will be signiﬁcantly altered by advances in
imaging during the next decade.
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